Should We Try Antiandrogen Withdrawal in Castration-Resistant Prostate Cancer Patients? Insights From a Retrospective Study.

BACKGROUND - It remains uncertain whether those with response to antiandrogen withdrawal (AAW) have a better prognosis. We investigated the predictors of a better response to AAW and overall survival after acquiring resistance to first-line androgen deprivation therapy inpatients with castration-resistant prostate cancer (CRPC).

PATIENT AND METHODS - We retrospectively reviewed the medical records of 87 CRPC patients treated at Keio University Hospital. Sixty-seven of 87 CRPC patients underwent AAW. We analyzed clinicopathologic parameters to identify predictors of survival in CRPC patients and investigated predictors of good response to AAW.

RESULTS - Younger age, longer duration of androgen deprivation therapy before CRPC development, and better response to AAW were independent favorable prognostic factors for overall survival. Although better response to AAW was a favorable prognostic factor in this study, trying AAW was not significantly related to overall survival. Duration of hormone therapy was significantly longer in those whose disease responded to AAW (69.9 ± 11.0 months) than those with no response (45.3 ± 5.2 months).

CONCLUSIONS - The prognostic benefit of AAW was not clearly determined in this study. However, AAW might be beneficial in patients who have favorable prognostic factors for a response to AAW-that is, those who have received hormone therapy for a long period. However, AAW should not be done in patients who do not have favorable factors and who had a high prostate-specific antigen level at the time of their prostate cancer diagnosis.

Clinical genitourinary cancer. 2016 Feb 23 [Epub ahead of print]

Hiroshi Hongo, Takeo Kosaka, Ryuichi Mizuno, Taisuke Ezaki, Kazuhiro Matsumoto, Shinya Morita, Kazunobu Shinoda, Toshiaki Shinojima, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya

Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan. Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan., Keio University School of Medicine, Shinjuku-ku, Japan.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe